Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
13 août 2024 16h05 HE
|
Senti Biosciences, Inc.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
05 août 2024 08h05 HE
|
Senti Biosciences, Inc.
Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM).
Senti Bio Announces Reverse Stock Split
16 juil. 2024 08h30 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using...
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
01 juil. 2024 08h05 HE
|
Senti Biosciences, Inc.
The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202.
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
13 mai 2024 08h15 HE
|
Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
09 mai 2024 16h05 HE
|
Senti Biosciences, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
30 avr. 2024 08h05 HE
|
Senti Biosciences, Inc.
Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
21 mars 2024 16h05 HE
|
Senti Biosciences, Inc.
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
05 janv. 2024 16h05 HE
|
Senti Biosciences, Inc.
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024...
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
22 déc. 2023 06h30 HE
|
Senti Biosciences, Inc.
– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a...